Lymphadenectomy Does Not Improve Survival in Advanced Ovarian Cancer


Systematic lymphadenectomy in patients with advanced ovarian cancer and complete resection does not improve progression-free or overall survival, and should be omitted, according to results of a new study.

[[{"type":"media","view_mode":"media_crop","fid":"60306","attributes":{"alt":"Philipp Harter, MD, PhD, presenting results of the study; photo © ASCO/Scott Morgan 2017","class":"media-image","id":"media_crop_8421697621752","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"7613","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":"Philipp Harter, MD, PhD, presenting results of the study; photo © ASCO/Scott Morgan 2017","typeof":"foaf:Image"}}]]

Systematic lymphadenectomy (LNE) in patients with advanced ovarian cancer and complete resection does not improve progression-free or overall survival (OS), and should be omitted, according to results of a new study.

“Upfront surgery aiming at macroscopic complete resection is the goal in patients with primary advanced ovarian cancer,” said Philipp Harter, MD, PhD, of the Kliniken Essen-Mitte in Germany, during his presentation of the LION study (abstract 5500) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. Previous studies have showed mixed results regarding LNE in patients with otherwise complete resection.

The LION trial randomized 650 patients with advanced epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention-to-treat cohort), or no LNE (324 patients in intention-to-treat cohort). Patients were well matched between the groups, with a median age of 60 years, primarily ECOG 0 performance status, and mostly grade 2/3 serous histology.

Lymph node metastases were detected in 55.7% of the LNE patients. The median number of resected lymph nodes in those patients was 57 (22 para-aortic, 35 pelvic). The LNE patients had a median of 1 hour more of surgical duration (P < .001) and significantly more blood loss during surgery (P < .001). They also required more transfusions, experienced more infections requiring antibiotics (P = .03), and experienced a higher rate of 60-day postoperative mortality (3.1% vs 0.9%; P = .049).

These differences, however, did not translate into any difference with regard to survival outcomes. The full cohort had a median progression-free survival of 25.5 months, and a median OS of 67.2 months, with a 5-year OS rate of 55.9%. The median OS in LNE patients was 65.5 months, compared with 69.2 months with no LNE, yielding a hazard ratio of 1.057 (95% CI, 0.833–1.341). Similarly, the median progression-free survival in both groups was the same, at 25.5 months, for an HR of 1.106 (95% CI, 0.915–1.338).

A quality-of-life analysis using the QLQ-C30 Global Health Status instrument found nearly identical results in the two groups.

“Our data indicate that systematic LNE of clinical negative lymph nodes in patients with advanced ovarian cancer and complete resection should be omitted,” Harter concluded.

Ritu Salani, MD, MBA, of the Ohio State University Wexner Medical Center, was the Discussant for the session, and she agreed that these data suggest omitting LNE is acceptable. “I always thought that the lymph nodes represented a sanctuary for ovarian cancer and this is why we removed them, and I think this actually debunks that theory,” she said, adding that doing so would likely have cost-effectiveness benefits as well.

Related Videos
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
In addition to potentially moving mirvetuximab into earlier lines of treatment for those with platinum-sensitive ovarian cancer, Ritu Salani, MD, also discusses combining the agent with carboplatin to decrease toxicities and improve quality of life.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content